anti-xCT antibody-drug conjugate

Anti-xCT antibody-drug conjugate is an investigational **antibody-drug conjugate** developed by Agilvax for oncology. It is designed to bind **xCT**, the cystine/glutamate antiporter light chain encoded by **SLC7A11**, which is overexpressed in multiple cancers and is associated with tumor redox control, cystine uptake, glutathione synthesis, metastasis, treatment resistance, and poor prognosis. Publicly available Agilvax materials describe an anti-xCT monoclonal antibody program, including the lead antibody **M5**, and indicate that the company subsequently used its anti-xCT antibodies to generate ADC candidates for xCT-expressing tumors. The specific payload, linker, and clinical candidate identity have not been clearly disclosed in the accessible sources, but the therapeutic concept is targeted delivery of a cytotoxic warhead to xCT-positive cancer cells while also exploiting xCT biology as a cancer-selective surface target.

Other names

anti-xCT antibody-drug conjugateanti-xCT-ADC